Category Archives: Science

What Does the Science Say About Nicotine Pouches? Lower Toxicant Exposure, Remaining Uncertainties, and the Case for Proportionate Regulation

As nicotine pouches continue to expand across global markets, policymakers and public health stakeholders are increasingly asking important questions about their safety profile, long-term health implications, and appropriate regulation. A recent review published in Tobacco Induced Diseases, “Research on the Safety Risk of Oral Nicotine Products and Its Prospects,” contributes to this growing evidence base…

Who Is Considering Switching to Nicotine Pouches?

New Research Offers Insights into Consumer Interest and Smoking Status As nicotine pouches continue to gain attention from regulators, researchers, and public health stakeholders, an important question remains: who is actually interested in using them? Much of the policy debate surrounding nicotine pouches focuses on potential risks, youth uptake, and regulatory controls. However, understanding who…

What Does the Evidence Say About Nicotine Pouches?

Examining the Scientific Case for Tobacco Harm Reduction As nicotine pouches become an increasingly prominent feature of nicotine policy discussions worldwide, debate often moves faster than the science itself. Regulators, public health stakeholders, researchers, and policymakers are grappling with important questions about risk, cessation, consumer behaviour, and appropriate regulatory frameworks. While long-term epidemiological evidence is…

Predicting Nicotine Delivery: What a New Scientific Model Could Mean for Product Assessment and Regulation

As nicotine products continue to evolve, regulators and researchers face a recurring challenge: how can the performance of new products be evaluated efficiently, accurately, and consistently without relying exclusively on costly and time-consuming human clinical studies? A newly published study in Scientific Reports offers an interesting contribution to that discussion. Rather than focusing on consumer…

When the IMF Recognises the Risk Continuum: Why Nicotine Products Should Not Be Regulated as if They Are Equally Harmful

Discussions about nicotine regulation often become polarized. Some policymakers argue that all nicotine products should be treated similarly because they contain an addictive substance. Others argue that regulation should reflect differences in risk between products. A recent analysis from the International Monetary Fund (IMF) offers an important contribution to this debate. Published in Taxing Harmful…

Nicotine Summit USA 2026: Is Policy Finally Catching Up to Science?

The discussions emerging from Nicotine Summit USA 2026 suggest a growing recognition that nicotine policy may be entering a new phase, one in which regulatory systems are increasingly being challenged to reconcile long-standing public health objectives with evolving scientific evidence, consumer behavior, and market realities. As highlighted in recent reporting and commentary surrounding the Summit,…

Emerging Evidence on Nicotine Pouch Use: Insights from Recent U.S. Data

Recent research published in the American Journal of Preventive Medicine provides updated evidence on nicotine pouch use among adults in the United States, offering new insights into usage patterns, population trends, and potential regulatory considerations. The study, Nicotine Pouch Use Among U.S. Adults in 2023 and 2024, examines nationally representative data to assess how use…

Innovation and Acceptance: Understanding Consumer Choice in New Nicotine Products

At EVO NXT 2026, the Global Institute for Novel Nicotine hosted a panel session exploring the factors influencing consumer adoption of new nicotine products, focusing on innovation, accessibility, and regulatory context. The session was moderated by Marc Reisner and featured contributions from Waqas Khan, Vincent Reid, and John Dunne, offering perspectives from manufacturing, distribution, and…

Tobacco Harm Reduction: Latest Science and Public Health Perspectives from EVO NXT 2026

At EVO NXT 2026, the Global Institute for Novel Nicotine opened its programme with a panel session examining the latest scientific evidence, regulatory frameworks, and public health considerations surrounding tobacco harm reduction. The session was moderated by Philipp Markl and featured contributions from Dr Sydney Hiller, Sairah Salim-Sartoni, and John Dunne, bringing together perspectives from…

Who Is Considering Switching to Nicotine Pouches?

New U.S. evidence highlights patterns relevant to harm reduction policy As nicotine pouches (ONPs) continue to expand in the United States, understanding how adult smokers engage with these products is becoming increasingly important for evidence-based regulation. A recent peer-reviewed study using nationally representative data from the Population Assessment of Tobacco and Health (PATH) Study provides…